Ticker: GSK

GSK

Pharma Healthcare Drug Manufacturers - General
Price 51.35
Reco Sell Potential 43 Risk 65 Updated 2026-07-26

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

GSK is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. Its core products include prescription medications for various therapeutic areas, vaccines for infectious diseases, and over-the-counter consumer health products. Major business segments consist of Pharmaceuticals, Vaccines, and Consumer Healthcare, with revenue primarily generated from prescription drugs and vaccines. The company aims to address health challenges through innovation and research.

Investment Profile

GSK's stock presents a neutral investment profile, appealing to investors seeking a balance between growth and dividends. The company offers a moderate dividend yield, which may attract income-focused investors, while its pharmaceutical innovations suggest potential for future growth. However, recent revenue declines indicate caution for growth-oriented investors. Overall, it may suit those looking for stability rather than aggressive growth.

Fundamental metrics (experimental) Updated: 2026-07-24
EPS (TTM) — earnings per share for the last 12 months, $
3.42
Revenue QoQ — quarter-over-quarter revenue growth
-11.5%
EPS surprise
6.9%
20d volatility
1.7%
Dividend yield
3.5%
last ex-date
2026-05-15
AI recommendation changes
Date Before After Reason
2026-07-19 Buy Sell Weak fundamentals and negative momentum raise concerns.
2026-07-17 Hold Buy Stable dividend, but revenue decline raises concerns.
2026-07-05 Buy Hold Stable dividend, but mixed performance and fundamentals.
Analyst forecasts
Date Analyst Action Target Price Then
2025-10-30 CFRA Update — → 53 46.67
News Page 1 of 1
JPMorgan Chase GSK

JPMorgan Analysts Highlight Reopening Biotech IPO Market Amid Continued Big Pharma M&A Activity

The biotech sector is experiencing a resurgence in public market activity, but many leading companies may prefer acquisition by larger pharmaceutical firms over pursuing initial public offerings (IPOs). This trend reflects a selective investment climate and a strategic shift in how biotech firms approach growth and funding.
Micron J.M. Smucker GSK Alibaba Vail Resorts Qualcomm

Stocks to Watch: Nuvalent Soars on GSK Acquisition Announcement, J.M. Smucker Reports Strong Earnings, SailPoint Issues Weak Guidance

Nuvalent's shares surged nearly 39% following GSK's announcement of a $10.6 billion acquisition, highlighting significant market activity in the pharmaceutical sector. Meanwhile, J.M. Smucker's strong earnings report positively impacted its stock, while SailPoint's disappointing guidance led to a notable decline in its shares.